<DOC>
	<DOCNO>NCT02440074</DOCNO>
	<brief_summary>This trial pretend validate clinical use bioengineered product compose mesenchymal stem cell produce Instituto de Biologia Genetica Molecular ( IBGM ) , Valladolid ( MSV , already approve Spanish Regulatory Agency three previous clinical trial ) cross-linked matrix autologous plasma patent The Blood Tissue Bank Asturias ( WO2008/ 119855 ) bone maxillary cyst refill . These two group collaborate present project team Maxillofacial Surgery Hospital Universitario del RÃ­o Hortega , lead clinical trial deal medical aspect . The propose trial base positive result obtain previous animal study perform present multidisciplinary team . A phase I / II clinical trial 10 patient suffer bone cysts maxillofacial region propose . Autologous mesenchymal stem cell isolate bone marrow sample seed autologous plasma matrix cultivate 3 week . At time , cyst remove surgery cavity fill protein matrix contain mesenchymal cell . Follow test conduct 3 week , 3 6 month follow evolution cavity panoramic radiography computerize tomography scan .</brief_summary>
	<brief_title>Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells ( MSV )</brief_title>
	<detailed_description>The propose test base previous animal experiment positive result multidisciplinary team applicant , whose result present paragraph 2.6 ( group result Valladolid ) Annex I ( group result Oviedo ) . The investigator propose phase I-II trial 10 patient common condition difficult solve volumetric regeneration therapy , bone cyst maxillofacial region . Autologous mesenchymal cell isolated sample obtain cancellous bone tuberosity intraoral mandibular later expansion , convey matrix autologous serum . The total process take 6-8 week . After time , perform osteotomy enucleation cyst local anesthesia residual cavity fill bioimplant contain MSV-H. Once bioimplant , clinical control 2 week , 2 6 month , follow evolution regeneration bone cavity panoramic radiograph CT scan . This project propose novel approach therapy twice , combine tissue engineering protocol ( bioimplant ) consist autologous mesenchymal cell already approve unit cell production Valladolid ( MSV-H ) , new protein matrix obtain autologous serum crosslinked order stimulate regenerative capacity maxillary cystic bone defect .</detailed_description>
	<mesh_term>Spinal Diseases</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Degenerative disease one two lumbar disc predominant back pain conservative treatment ( physical medical ) 6 month . Fibrous ring capable hold cell implantation , demonstrate Magnetic Resonance Imaging ( MRI ; stag 2 , 3 4 Adams ) . Decrease disc height 20 % ( radiographic measurement side image ) . Absence spinal infection . Haematological biochemical analysis wit significant alteration contraindicate intervention . The patient able understand nature study . Informed write consent patient . Age 75 18 legally dependent Allergy gentamicin , bovine , cattle horse serum . Congenital acquire disease lead spine deformation may upset cell application . Spinal segmental instability , spinal canal stenosis , isthmus pathology condition may compromise study Modic III change MRI image ( 31 ) . Overweight body mass index ( mass Kg/size m2 ) great 35 ( obesity grade II ) . Pregnancy breastfeed Neoplasia Immunosuppression Participation another clinical trial treatment another investigational product within 30 day prior inclusion study . Other condition may , accord medical criterion , discourage participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Lumbar pain</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
</DOC>